Daniel Einhorn, MD, FACE, FACP
Sponsored by the Endocrine Society
Developed by Integritas Communications
This activity is supported by an educational grant from AstraZeneca.
Daniel Einhorn, MD, FACE, FACP
Clinical Professor of Medicine
University of California, San Diego
Diabetes and Endocrine Associates
Medical Director, Scripps Whittier Diabetes Institute
La Jolla, California
Dr. Daniel Einhorn is the President of the American College of Endocrinology and the Past President of the American Association of Clinical Endocrinologists. He is the Medical Director of the Scripps Whittier Diabetes Institute, Clinical Professor of Medicine at the University of California, San Diego, President, Diabetes and Endocrine Associates, as well as a Fellow of the American College of Physicians and the American College of Endocrinology.
Dr. Einhorn received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his internship in medicine and fellowships in endocrinology and in diabetes and metabolism at Harvard Medical School and Beth Israel Deaconess Medical Center.
The recipient of numerous awards from medical societies, industry, and community groups, Dr. Einhorn is a reviewer for many peer-reviewed journals and a national and international lecturer on diabetes, prediabetes, thyroid, sleep disorders, and clinical guidelines. He is the Editor of Clinics of North America for Type 2 Diabetes, Editor for Type 2 Diabetes in a Time of Pandemic for The Royal Society of Medicine Press, and an Associate Editor of the Journal of Diabetes.
Upon completion of this activity, learners will be better prepared to:
- Describe the etiologic causes and pathophysiologic mechanisms of congenital and acquired lipodystrophies
- Differentially diagnose various types of lipodystrophy based on the degree and pattern of adipose tissue loss, other clinical features, and appropriate laboratory testing
- Discuss evidence supporting pharmacologic treatment of lipodystrophy and associated metabolic disorders
- Tailor multimodal therapeutic regimens for lipodystrophy to address pathologic changes in fat distribution and associated metabolic disturbances
This continuing medical education should be of substantial interest to endocrinologists and other health care providers involved in the diagnosis and management of the heterogeneous group of lipodystrophy syndromes.
Statement of Independence
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter of this activity has no influence over the planning of this CME activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Daniel Einhorn, MD
The following SPC member who reviewed content for this activity reported no relevant financial relationships: Jeffrey Boord, MD, MPH
Endocrine Society and Integritas Communications staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment: The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages: When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
Policy On Unlabeled/Off-Label Use
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
Privacy and Confidentiality Statement
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. The Endocrine Society designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.